Fri, Nov 28, 2014, 4:09 AM EST - U.S. Markets open in 5 hrs 21 mins

Recent

% | $
Quotes you view appear here for quick access.

Ampio Pharmaceuticals, Inc. Message Board

racavalli 102 posts  |  Last Activity: Nov 26, 2014 11:41 AM Member since: Jul 31, 2012
  • Blog from The Street says AMPE is "EXTRAORDINARILY OVERSOLD" and is a BUY.

    Sentiment: Strong Buy

  • racavalli racavalli Sep 10, 2014 12:09 PM Flag

    I am confident that AMPIO WORKS VERY WELL but I am also confident that the biggest problem is . . . this low price creates a much higher probability of a large company making a bid for the whole company at a time when shareholders are frightened, discouraged and frustrated. Shareholders are now much more likely to accept a very low bid for the whole company. At the current price Ampio is EXTREMELY VULNERABLE TO A HOSTILE TAKEOVER.

    Ampio has admittedly been in detailed discussions with several potential big pharma partners so it is quite clear that they know all they need to know about just how solid these drugs are and now they are just weighing the difference between striking up a lucrative partnership agreement by year end . . . OR BUYING THE ENTIRE COMPANY FOR AN UNUSUALLY LOW PRICE.

    My guess, is that shareholders would now happily sell all their shares for $12 to $15 . . . that with only 52 million shares outstanding would translate to a ridiculously low price of between $500 and $800 million. By any standards, that would be a steal in the pharma industry to own 100% of Ampion for ALL INDICATIONS AND OPTINA AND EVERYTHING ELSE IN THEIR PIPELINE!

    Consider that management does not have anywhere near the shares it takes to control the company. They may have a staggered board but that does nothing to prevent a hostile takeover.

    I believe that management's short-sightedness about strong PR and market valuations is their Achilles heal and that it won' be long before they are swallowed up and disassembled for their parts.

    In my opinion, the die is cast and it is too late for management to wake up and respond now. Today's market cap is an astonishing $180 million and the price is very close to its ALL TIME LOW of $2.54

    Sentiment: Strong Buy

  • Reply to

    Where's Rich?

    by ampiooooooh Sep 9, 2014 12:24 PM
    racavalli racavalli Sep 9, 2014 1:15 PM Flag

    You are correct!

    This will turn out to be the best buying opportunity of all.

    The short players are doing well recently but now is not the time to get overconfident because the pendulum is about to swing the other way when least expected.

    Sentiment: Strong Buy

  • racavalli racavalli Sep 9, 2014 12:02 AM Flag

    Take a deep breath and realize that all other Ampion trial results are more than strong enough for a timely BLA filing and FDa approval.

    We should hear the FDa guidance for the BLA filing soon and meanwhile there are still a large nuber of surprises to the upside.

    This is nothing more than a RARE buying opportunity.

    Now is the time to take a stand.

    Just buy and simply hold. The downside risk is almost zero and the upside is off the charts.

    Just take another look at the MI data.

    And the other drugs.

    This is the best time ever to buy!

    Sentiment: Strong Buy

  • Looks like institutions are selling.

    Some margin selling is also occurring.

    Have we reached the bottom yet?

    Sentiment: Strong Buy

  • racavalli racavalli Sep 7, 2014 12:20 AM Flag

    I am confident they will file a claim for total losses with the appropriate insurance company and may even file a lawsuit for additional losses if necessary.

    Ampio is well known for very poorly written press releases but the recent debacle may wake them up to get a new writer because this last one cost them a hundred million dollars in market cap.

    Sentiment: Strong Buy

  • Reply to

    Lets make this perfectly clear...

    by jtinformed Sep 6, 2014 10:42 AM
    racavalli racavalli Sep 6, 2014 3:39 PM Flag

    MI

    began with 7 patients

    30 added

    now 300 being added

    Sentiment: Strong Buy

  • Based on last press release announcing Step Results, I suggest very strongly that the company have a different person write their press releases who can be clear and not easily misunderstood. That last press release cost the company a hundred million dollars in market cap. And most of Ampio's good news press releases usually make shares go down. This is not the way it is supposed to happen.

    Ampio needs to demand more from their attorneys instead of just accepting their muzzle that has cost Ampio hundreds of millions of dollars in market cap.

    Investors only buy stocks based on a promising future.

    The company must make statements that have some degree of forward looking structure or nobody will buy.

    The attorneys have been muzzling the company so they can't make ANY forward looking statements.

    If AMPE shares drop like they have recently, there are a dozen experienced and able law firms that will quickly file class action lawsuits that will cost millions and take years to resolve. even if the company is completely innocent of any wrongdoings.

    Just look at other successful companies and see how they are careful to properly balance their words to make promising forward looking statements

    IF YOU GOT IT . . . YOU GOTTA TOOT YOUR HORN OR NOBODY KNOWS!!!!!

    Let's all hope the company learns from the past.

    Sentiment: Strong Buy

  • racavalli racavalli Sep 6, 2014 2:57 PM Flag

    Based on relatively heavy volume since the announcement of the temperature excursions and the ensuing hit articles by AF and the poorly written and confusing press release by the company, it seems highly likely that there was a good degree of institutional selling.

    I am expecting to hear clarification from the company as to the FDA's guidance for the BLA filing.

    Food for thought is . . . the dose is tripled in the MI studies, but the safety appears to remain extremely good and we know the efficacy is off the charts. Remember what one of the physicians said about the MI outcomes . . . Ampion will change the way OAK patients are treated.

    The endpoints are very short and can still be achieved for an on time BLA filing in Q! 2015.

    Personally, I view blip as a blessing in disguise because the MI data is going to rocket approval, acceptance and demand for Ampion.

    And don't forget that the cartilage regeneration data is due in about 4 weeks that has the potential to be anywhere from mild to wild depending on what can be said about Ampion's ability to regenerate cartilage. If it recruits stem cells to the damaged are, then the implication is very broad that Ampion could be a major breakthrough in stem cell therapeutics because it may eliminate the need for harvesting stem cells.

    Sentiment: Strong Buy

  • racavalli racavalli Sep 5, 2014 12:26 PM Flag

    I would use this panic selling as a buying opportunity.

    This is a problem of investor misunderstanding caused by a procedural event that was out of the hands of the company that will most likely have no impact on the timing of the BLA filing in Q! 2015. There may also be some confusion due to management's poorly written press release and ensuing silence.

    We know from previous trial results that Ampion works very well, especially in multiple injections; we know it is safe; we know there is a huge unmet need that will motivate the FDA and drive the market; we know the factory to manufacture Ampion is approved and ready to go; we expect cartilage regeneration data in about 4 weeks; we would reasonably expect guidance from the FDA in the next few weeks that will clarify the current hysteria; we know the MI trials have short endpoints and will not cause any significant delay; we know that Optina results are expected in Q4.

    I believe there is more than enough known here to support a VERY strong buying opportunity.

    I have been following Ampio very closely for over three years and I am 100% convinced they are real and have the goods that blow away Wall Street very soon. I am also 100% convinced that Macaluso is doing his best to move the company forward on schedule and that he will succeed. MIke knows what he has and he is just as frustrated as we all are but now is a great opportunity for those with any powder left to buy more shares while they are very very cheap.

    Just my thoughts . . . obviously the street disagrees vehemently with me. You asked and this is my take.

    Sentiment: Strong Buy

  • racavalli racavalli Sep 4, 2014 5:38 PM Flag

    Your post is totally ineffective because EVERYBODY knows that large buyers or sellers NEVER reveal what they are going to buy or sell until AFTER.

    Really stupid post!

    Sentiment: Strong Buy

  • Reply to

    Free fall

    by justgreed Sep 3, 2014 4:00 PM
    racavalli racavalli Sep 3, 2014 4:46 PM Flag

    The longer the company remains silent, the steeper the fall!

    Sentiment: Strong Buy

  • racavalli racavalli Sep 3, 2014 2:43 PM Flag

    It's likely that management will clarify all the confusion soon and this will restore stability and rising prices again.

    Remember . . . prior trial results were strong enough that they caused CitiCorp and Jefferies to put up more than $70 million in cash recently.

    Remember . . . the FDa called the Spring Study results, "Robust".

    This does not sound like a loser.

    Buy while shares are as cheap as they are going to get. Now is the time to double down and take advantage of the gift looking us straight in the eye.

    Sentiment: Strong Buy

  • Even Feuerstein took his best shot and very little happened.

    In spite of all the uncertainty and in spite of managements silence that is ALWAYS construed VERY negatively, we know conclusively from prior trials that Ampion works well and that it is safe.

    All the noise today is from short interests taking advantage of easy pickings and the longs running into hiding because they are confused by terribly written press releases and feel like management has left them holding the bag. Unfortunately, the company listens to their lawyers too closely and will not fight back and we have seen how effective that is. Now they are under investigation because they have kept their mouth shut at the instructions of their attorneys and there will probably be more law firms threatening class action lawsuits in the coming days because the company continues to fumble just like nervous pro football team in a playoff game for their first time.

    Eventually Ampion and Optina will prove themselves and shareholders who held on through the flack and who even bought more will wind up the big winners.

    Shares were cheap at $8 and $10 but today we actually have a MICROCAP with a mature pipeline that has a total market cap of only $200 million.

    I predict sellers will be kicking themselves very hard in the future because they let the big one get away.

    I also predict a short term rally soon because shares are so oversold and compressed like a overtightened spring.

    Sentiment: Strong Buy

  • Reply to

    Subway chairman just invested $4M into PURE

    by bill750 Aug 28, 2014 11:38 AM
    racavalli racavalli Sep 3, 2014 10:37 AM Flag

    With close to $8 million in the bank and a giant fast food company as lead strategic investor, it's clear that PURE can expect to see sales skyrocket.

    PURE shares can expect to see much higher prices in the near term and are a strong buy.

    Sentiment: Strong Buy

  • Reply to

    Subway chairman just invested $4M into PURE

    by bill750 Aug 28, 2014 11:38 AM
    racavalli racavalli Sep 2, 2014 11:37 AM Flag

    That's a ridiculous statement because there is no way the current lack of liquidity in the marketplace for PURE shares will ever allow the $4 million investor to sell out.

    It is quite obvious this investment is for the long term. Plus, wealthy investors are not interested in short term profits because the tax rate is too high. Your statement is really very uneducated about investing in the market. Shrewd investors take tax advantages . . . foolish investors TRY to make a quick hit but usually fail.

    Better luck trying to bash PURE with something that at least makes sense or don't waste our time.

    Sentiment: Strong Buy

  • racavalli racavalli Sep 2, 2014 11:29 AM Flag

    The silence by SMAYCS4 is clear that he is lying and misleading to discredit BioLargo management and their technology. All of my claims made above can be supported with credible third party links whereas NONE of the claims made by SMAYCS4 can be supported by credible third party links.

    SMAYCS4 is in deep trouble and perhaps the others in collaboration with him as well.

    Sentiment: Strong Buy

  • Reply to

    Our resident basher

    by theeckman1 Sep 1, 2014 9:01 PM
    racavalli racavalli Sep 2, 2014 12:21 AM Flag

    Once again your information is misleading and incorrect. BioLargo has never taken in anywhere close to $64 million you quote and is probably closer to $10 million in actual cash. A company can't lose more than they take in, therefore, they have not lost anywhere close to the $64 million you claim. I'm sure you will find that any reported losses are tied to non cash flow items like share issuance etc from sales for funding capital raises to advance the company. I suggest you confer with an accountant who can explain this to you on his and your own time.

    Sentiment: Strong Buy

  • SMAYCS4 is trying his best to discredit BioLargo, Ampio Pharmaceuticals (AMPE), Cesca Therapeutics (KOOL), PURE BIOSCIENCE (PURE), and Millennium Healthcare (MHCC). He calls them SCAMS.

    His comments are false and misleading and can cost investors a great deal in lost opportunity.

    If AMPE were a SCAM, would the large investment bankers, Citicorp and Jefferies, have invested over $70 million this year? Ampio has proven extraordinary efficacy and safety of Ampion and Optina in prior trials and is on track for BLA and NDA filings for FDA approvals next year.

    If Cesca were a scam, would Maxim and H.C. Wainright have invested $17 million this year? Cesca has delivered the most powerful clinical trial results EVER for CLI and other indications and I believe will be the leader in stem cell technology unless Ampio's drug Ampion is proven to be as effective as stem cells from harvesting because Ampion may be found to completely eliminate the need for harvesting.

    If PURE Bioscience was a scam, would the owner of the giant Subway have just invested $4 million?

    If Millennium Healthcare were a scam, would 1,300 physician offices have signed up under long-term contract for Millennium’s FDA approved diagnostics?

    Wouldn’t the SEC be prosecuting all these companies if they were a scam? Of course they would, but they are not . . . because these companies, including BioLargo, are legitimate, honest and have very high integrity. Something clearly missing in SMAYCS4.

    I only follow companies that I believe in strongly and BioLargo is one that I am convinced will be shown to have world changing technology that will help solve the growing global water problem. Less

    Sentiment: Strong Buy

  • Franchise Brands is owned by the owner of Subway and they just invested $4 million in PURE.

    They know far more abut the restaurant business than anybody, including the hecklers on this site.

    Their investment is a strong signal that PURE is a strong buy.

    SDC is the first major breakthrough on food safety in decades and it works so good that the owner of Subway is investing and don't be surprised when Subway begins ordering large quantities of SDC.

    Expect sales to begin ramping up later this year exactly as PURE management has forecast.

    SDC is going to become dominant in the giant food industry and once it is recognized for its unrivaled germ killing power coupled with complete safety, it will dominate the large antimicrobial market worldwide.

    PURE is a very strong buy.

    Sentiment: Strong Buy

AMPE
3.68+0.2700(+7.92%)Nov 26 4:01 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.